This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells. Antiidiotypic antibodies bearing the internal image of an antigen expressed on the surface of the tumor are suited to this approach.
To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported."""@en ; dct:identifier "drugbank:DB05489" ; dct:title "ACA 125"@en ; adv:Drug ; rdfs:label "ACA 125 [drugbank:DB05489]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05489> . }